Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
 formerly known as PlasmaTech Biopharmaceuticals, Inc. (PTBI) - EconoTimes)
NEW YORK, Dec. 16, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed on behalf of purchasers of: (1) PlasmaTech Biopharmaceuticals, Inc. securities (old symbol PTBI) from March 31, 2015 through June 19, 2015, both dates inclusive (the “PlasmaTech Class Period”); and/or (2) Abeona Therapeutics Inc. securities (Nasdaq:ABEO) from June 22, 2015 through December 9, 2016, both dates inclusive (the “Abeona Class Period” ) and together with the PlasmaTech Class Period, the (“Class Period”).
Abeona Therapeutics Inc. was formerly known as PlasmaTech Biopharmaceuticals, Inc. The lawsuit seeks to recover damages for Abeona investors under the federal securities laws for both class periods.
According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the science behind Abeona’s proposed gene therapy treatment for Sanfilippo syndrome is unviable; (2) Steven H. Rouhandeh, Abeona’s Executive Chairman and Principal Executive Officer, previously worked in a high ranking position for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks; and (3) as a result, Defendants’ statements about Abeona’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On December 12, 2016, analyst firm Mako Research published a report on Abeona asserting, among other things, that Abeona’s science underpinning its gene therapy approach is unviable and Steven H. Rouhandeh previously worked in a position of authority at D. Blech & Co. — a firm named after now-convicted felon David Blech. On this news, shares of Abeona fell $0.70 per share or over 13% from its previous closing price to close at $4.45 per share on December 12, 2016, damaging investors.
If you wish to serve as lead plaintiff, you must move the Court no later than February 14, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
